HD16 for Early Stage Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Bleomycin; Dacarbazine; Doxorubicin; Liposomal doxorubicin; Vincristine

Criteria

Inclusion Criteria:

• Hodgkin Lymphoma

• CS I, II without risk factors

• large mediastinal mass (> 1/3 of maximum transverse thorax diameter)

• extranodal involvement

• elevated ESR

• 3 or more involved nodal areas

• Written informed consent

Exclusion Criteria:

• Leucocytes < 3000/µl

• Platelets < 100000/µl

• Hodgkin Lymphoma as composite lymphoma

• Activity index (WHO) > 2